JMP Securities Starts Incyte (INCY) at Market Outperform
More News related to INCY
- Incyte Reports Third Quarter 2009 Financial Results and Provides Update on Drug Development Programs
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Leerink Swann Initiates Coverage on Incyte Corp (INCY) with an Outperform; Street Under-Appreciating Potential
- Cowen & Co Upgrades Incyte (INCY) to Outperform
- Trading Outlook for Incyte Corp. Issued by StockPreacher.com
More News related to New Coverage
- Morgan Stanley Initiates Coverage on Williams Companies (WMB) with an Overweight
- Morgan Stanley Starts ONEOK (OKE) at Underweight, $40 Price Target
- Broadpoint.Amtech Initiates Coverage on Willbros Group (WG) with a Buy; Leading North American Pipeline Contractor
- Miller Tabak Initiates Coverage on Oclaro (OCLR) with a Buy
- Natixis Bleichroeder Initiates Coverage on Gen-Probe (GPRO) with a Buy
JMP Securities initiates coverage on Incyte (Nasdaq: INCY) with a Market Outperform rating.
Incyte Corporation operates as a drug discovery and development company, which focuses on developing proprietary small molecule drugs to treat human immunodeficiency virus (HIV), diabetes, oncology, and inflammation diseases. [BCS]
Related Categories
New CoverageStocks Mentioned
+0.13Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
